Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Santoro, F; Mugnai, G; Perrotta, L; Kovacs, B; Dinshaw, L; Del, Castillo, AM; Jungen, C; Kurath-Koller, S; Stojković, S; Vandenberk, B; Vernooy, K.
Catheter ablation vs. anti-arrhythmic drug therapy for ventricular tachycardia in ischaemic heart disease: a meta-analysis of randomized controlled trials.
Europace. 2025; 27(12): Doi: 10.1093/europace/euaf302 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Kurath-Koller Stefan

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

AIMS: Ventricular tachycardia (VT) in ischaemic heart disease (IHD) requires complex management strategies including catheter ablation (CA) and anti-arrhythmic drugs (AADs). The aim of this study is to compare efficacy and safety of CA vs. AADs in patients with IHD and VT. METHODS AND RESULTS: We performed a meta-analysis of randomized controlled trials (RCTs) enrolling patients with IHD and ICD randomized to CA or AADs. Primary outcome was appropriate ICD therapy. Secondary outcomes included inappropriate ICD therapy, cardiovascular (CV) re-hospitalization, all-cause/CV mortality, and adverse events. Subgroup analyses were conducted for amiodarone and sotalol, with an exploratory evaluation of a composite endpoint (ICD shock, VT storm, all-cause death). Four RCTs including 947 patients (mean age 68 ± 2 years; 93% male) were analysed. CA significantly reduced the risk of appropriate ICD therapy compared with AADs (149/470 [31.7%] vs. 229/477 [48.0%]; RR 0.81; 95% CI [0.67, 0.97]; P = 0.02). Among secondary outcomes, CA decreased the incidence of CV re-hospitalization [RR 0.84; 95% CI (0.72, 0.99); P = 0.04] and adverse events [RR 0.42; 95% CI (0.28, 0.62); P < 0.01], while no differences were observed in all-cause/CV mortality and inappropriate ICD therapy. In subgroup analyses, CA was superior to sotalol in reducing the composite endpoint of ICD shock, VT storm and all-cause death [RR: 0.82, 95% CI (0.69, 0.98), P = 0.03]; whereas, no significant benefit was seen compared to amiodarone [RR: 0.92; 95% CI (0.78, 1.09), P = 0.32]. CONCLUSION: In ischaemic heart disease and VT, CA compared with anti-arrhythmic drugs is associated with a reduction of appropriate ICD therapy, cardiovascular re-hospitalization, and adverse events with benefits most evident versus sotalol.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Anti-Arrhythmia Agents - therapeutic use, adverse effects

Tachycardia, Ventricular - therapy, mortality, physiopathology, diagnosis, etiology

Randomized Controlled Trials as Topic - administration & dosage

Myocardial Ischemia - complications, mortality, therapy, diagnosis

Catheter Ablation - adverse effects, mortality

Male - administration & dosage

Aged - administration & dosage

Defibrillators, Implantable - administration & dosage

Treatment Outcome - administration & dosage

Female - administration & dosage

Risk Factors - administration & dosage

Sotalol - therapeutic use

Middle Aged - administration & dosage

Find related publications in this database (Keywords)

Ventricular tachycardia

Catheter ablation

Anti-arrhythmic drugs

Amiodarone

Sotalol

Implantable cardioverter-defibrillator

Ischaemic cardiomyopathy

Re-hospitalization

© Med Uni Graz • Impressum